Corticosteroid Therapy in Neonatal Septic Shock-Do We Prevent Death?

Am J Perinatol. 2018 Jan;35(2):146-151. doi: 10.1055/s-0037-1606188. Epub 2017 Aug 24.

Abstract

Objective: The aim was to compare survival of patients with septic shock receiving or not hydrocortisone (HC) and to analyze the hemodynamic response to HC.

Study design: It is a retrospective study of 62 premature neonates with septic shock (confirmed bacteremia) and/or necrotizing enterocolitis (NEC) stage 2 and above receiving inotropes with or without HC. We analyzed survival and hemodynamic response to HC.

Results: Thirty-nine (63%) premature neonates received HC and were compared with 23 (37%) who only received inotropes. Vasoactive index score (VAI) decreased and blood pressure, urine output, and oxygen requirements improved significantly following HC. Despite receiving more inotropes (VAI of 33 [20-53] vs 10 [8-20], p < 0.001), being more premature (26 ± 2 vs 27 ± 2 weeks, p = 0.02) and more frequently having NEC (64 vs 26%, p = 0.004), patients who received HC had similar survival from septic episode (death: 22% vs 41%, p = 0.12). However, patients receiving HC during their sepsis were less likely to survive at their 1-year postmenstrual age follow-up when accounted for gestational age (GA) at birth and duration of inotropes (hazard ratio 6.08 p = 0.01).

Conclusion: HC was used in infants with increased inotropic support. HC during septic shock was associated with similar survival from episode, but with decreased survival at 1-year postmenstrual age.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enterocolitis, Necrotizing / drug therapy*
  • Enterocolitis, Necrotizing / mortality
  • Female
  • Hemodynamics
  • Humans
  • Hydrocortisone / therapeutic use*
  • Infant
  • Infant Mortality*
  • Infant, Newborn
  • Male
  • Proportional Hazards Models
  • Retrospective Studies
  • Severity of Illness Index
  • Shock, Septic / drug therapy*
  • Shock, Septic / mortality

Substances

  • Hydrocortisone